Key facts
- This page summarizes Henry Louis Salomonsky's Form 3 filing for Immune Therapeutics, Inc..
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Dec 2022, 15:46.
Henry Louis Salomonsky - 25 Jul 2022 Form 3 Insider Report for Immune Therapeutics, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 25 Jul 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Henry Louis Salomonsky
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Henry Louis Salomonsky filed Form 3 for Immune Therapeutics, Inc. on 15 Dec 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMUN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20
- Date
- 25 Jul 2022
- Ownership
- Direct
IMUN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 12,168,880
- Date
- 25 Jul 2022
- Ownership
- By trust
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These shares are owned directly by the H. Louis Salomonsky Jr. Revocable Trust, a ten percent owner of the issuer, and indirectly by Henry Louis Salomonsky as trustee of the trust. Henry Louis Salomonsky is a director and ten percent owner of the issuer.